Welcome to our dedicated page for Co-Diagnostics news (Ticker: CODX), a resource for investors and traders seeking the latest updates and insights on Co-Diagnostics stock.
Co-Diagnostics, Inc. (NASDAQ: CODX) is a molecular diagnostics company that develops, manufactures and markets technologies for tests designed to detect and analyze nucleic acid molecules (DNA or RNA). Its news flow centers on progress in molecular assay development, regulatory pathways for its Co-Dx PCR platform, intellectual property milestones, joint ventures, and capital markets activity.
Readers following CODX news can expect regular updates on the company’s point-of-care Co-Dx PCR platform, including the Co-Dx PCR Home and Co-Dx PCR Pro instruments, associated tests, and mobile app, all of which the company notes are subject to regulatory review and not yet available for sale. Recent announcements have covered clinical evaluations for the Co-Dx PCR Flu A/B, COVID-19, RSV upper respiratory multiplex test kit, preclinical and planned clinical performance studies for tuberculosis (MTB) and HPV tests on the platform, and the development of a proprietary sample preparation instrument for point-of-care use.
Co-Diagnostics also issues news about its joint ventures and international collaborations. Updates include activities of CoSara Diagnostics Pvt. Ltd. in India, such as participation in regional conferences and capacity-building workshops, and the formation of CoMira Diagnostics with Arabian Eagle Manufacturing to research, develop, manufacture, assemble, distribute and commercialize Co-Dx technologies in the Kingdom of Saudi Arabia and 18 MENA nations.
Investors and observers will find coverage of intellectual property developments, such as the grant of Australian Patent No. AU2022270084A1 for the Co-Dx PCR platform, as well as corporate and financing events disclosed through press releases and SEC filings. News items may also highlight the company’s AI business unit and presentations at industry conferences on portable, cloud-connected PCR diagnostics and AI integration. This page aggregates these updates so that users can review CODX-related announcements and regulatory communications in one place.
Co-Diagnostics (Nasdaq: CODX) will join a Utah delegation at Medical Korea 2026 in Seoul, March 19–22, 2026. Co-Dx will participate in a healthcare roundtable on March 19 and present its upcoming Co-Dx PCR point-of-care platform. Attendance is partly supported by a WTC Utah grant.
The Co-Dx PCR platform remains under regulatory review and is not yet available for sale.
Co-Diagnostics (Nasdaq: CODX) announced that the Japan Patent Office granted Japanese Patent No. 7797537 on March 12, 2026, titled "Systems, Methods, and Apparatus for Automated Self-Contained Biological Analysis."
The patent, originally registered December 26, 2025, contains 34 claims covering the Co-Dx PCR Pro instrument, proprietary test cups, and core automated point-of-care PCR platform technologies, and follows a 2025 Australian patent. The company says this expands international IP protection while the platform remains subject to regulatory review and is not yet for sale.
Co-Diagnostics (Nasdaq: CODX) announced it regained compliance with Nasdaq listing rules, including the $1.00 bid price requirement, after receiving formal notice on March 9, 2026. Trading will resume on Nasdaq effective March 11, 2026. The company continues clinical performance studies and regulatory review of its Co-Dx PCR platform.
Co-Diagnostics (OTC: CODX) will exhibit at World Health Expo Labs Dubai February 10–13, 2026 at the Dubai World Trade Centre, Booth S17.C79.
The appearance follows formation of joint venture CoMira Diagnostics to localize manufacturing and distribution across Saudi Arabia and 18 MENA countries. The company is highlighting its upcoming Co-Dx PCR platform, currently in U.S. clinical studies and subject to regulatory review.
Co-Diagnostics (OTC: CODX) joint venture CoSara received a CDSCO Form MD-5 license on Feb 5, 2026, authorizing manufacture of the CoSara PCR Pro real-time PCR point-of-care instrument at its Ranoli, India facility for sale or distribution.
This instrument license is described as the final CDSCO instrument approval required before commercialization; the CoSara-branded PCR Pro will be manufactured and distributed in India and run with CoSara PCR test kits, which require separate regulatory clearance prior to use as IVDs.
Co-Diagnostics (OTC: CODX) said its joint venture CoSara has received ISO 13485:2016 certification for its Vadodara, India manufacturing facility on Feb 4, 2026. The certification validates the joint venture's quality management system and supports regulatory submissions for an upcoming PCR platform and associated tests.
Company staff visited India to finalize MTB and HPV test software, inspect clinical study sites, and support manufacturing lines; the PCR platform remains subject to FDA and other regulatory review and is not yet for sale.
Co-Diagnostics (Nasdaq: CODX) said its Indian joint venture CoSara Diagnostics expanded distributor engagement by exhibiting at two regional conferences (GAPM in Gujarat on Jan 10-11 and ACLAP in Maharashtra) and has an existing network of over 40 distributors across India.
CoSara is preparing to assist in clinical performance studies for the Co-Dx PCR Mycobacterium Tuberculosis (MTB) Test on the Co-Dx PCR platform and will participate in manufacturing the PCR Pro instrument and MTB test cups to align with India’s "Make in India" initiative. The Co-Dx PCR platform remains subject to review by the FDA and other regulators and is not yet available for sale.
Co-Diagnostics (Nasdaq: CODX) filed a Certificate of Amendment to effect a 1-for-30 reverse stock split, effective at 12:01 a.m. ET on January 2, 2026. The company's common stock will continue trading on Nasdaq under the symbol CODX and will trade on a split-adjusted basis when markets open on January 2, 2026. The reverse split was approved by stockholders at a special meeting on December 5, 2025 within an authorized range of 1-for-2 to 1-for-30.
The reverse split is intended to enable the company to regain compliance with Nasdaq's $1.00 minimum bid price requirement. At the effective time, every 30 issued and outstanding shares will combine into one share; par value per share remains unchanged. The action will adjust shares available under equity incentive plans, change option and warrant share counts and increase exercise prices, and result in a new CUSIP of 189763 204. Fractional shares will be rounded up to the next whole share.
Co-Diagnostics (Nasdaq: CODX) announced that the Australian Patent Office granted Australian Patent No. AU2022270084A1, strengthening IP around its Co-Dx PCR platform.
The patent, filed in May 2022 and granted in June 2025, covers the design and operation of the Co-Dx PCR Pro instrument and test cups and protects the company’s Co-Primers® approach for nucleic acid detection. The grant provides regional protection in Australia as the company advances a Co-Dx PCR Flu A/B, COVID, RSV multiplex test currently in clinical performance testing. The platform remains under FDA/other regulatory review and is not yet for sale.
Co-Diagnostics (Nasdaq: CODX) said its joint venture CoSara Diagnostics was invited to the 2nd Advanced TB Diagnostics Course in Chennai, India, held Dec 15–19, 2025 at ICMR–NIRT.
The multi-day workshop, hosted with McGill International TB Centre and global partners, brings national TB programs, diagnostics developers, industry and experts from WHO, Gates Foundation, FIND and academic institutions to review the diagnostics value chain, new technologies, cost-effectiveness modeling, policy development and strategies to close the TB case-finding gap across the South‑East Asian Region.